Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients—A Randomized Phase 2 Clinical Trial.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3682, doi. 10.3390/jcm9113682

By:

• Brownstein, Michael J.;
• Simon, Neal G.;
• Long, Jeffrey D.;
• Yankey, Jon;
• Maibach, Hilda T.;
• Cudkowicz, Merit;
• Coffey, Christopher;
• Conwit, Robin A.;
• Lungu, Codrin;
• Anderson, Karen E.;
• Hersch, Steven M.;
• Ecklund, Dixie J.;
• Damiano, Eve M.;
• Itzkowitz, Debra E.;
• Lu, Shifang;
• Chase, Marianne K.;
• Shefner, Jeremy M.;
• McGarry, Andrew;
• Thornell, Brenda;
• Gladden, Catherine

Publication type:

Article